Literature DB >> 65452

Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.

R E Gonsette, L Demonty, P Delmotte.   

Abstract

140 MS patients were treated with intensive I.V. cyclophosphamide immunotherapy and 110 were followed over 2-4 years. Annual relapse rate incidence was calculated over a period of 2 years before and after treatment and repeated neurological scores were made during this period. The conclusions are that 62% of the patients were stabilized during 2-4 years and that clinical improvement of the neurological signs was observed in most of the cases. It is concluded that intensive immunosuppression is able to interfere with the pathological processes involved in the pathogenesis of disseminated sclerosis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 65452     DOI: 10.1007/BF00316148

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  33 in total

1.  Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response.

Authors:  E M Lance; M Kremer; J Abbosh; V E Jones; S Knight; P B Medawar
Journal:  Clin Exp Immunol       Date:  1975-07       Impact factor: 4.330

2.  Immune status of patients with multiple sclerosis. Analysis of primary and established immune responses in 24 patients.

Authors:  L E Davis; E M Hersh; J E Curtis; R E Lynch; D K Ziegler; J W Neumann; T D Chin
Journal:  Neurology       Date:  1972-10       Impact factor: 9.910

3.  [Critic study of multiple sclerosis treatment by chlorambucil and intraspinal corticotherapy. Apropos of 100 cases followed up from 2 to 9 years].

Authors:  J Sigwald; A Mazalton; C Raymondeaud; C Piot; C Jacquillat
Journal:  Rev Neurol (Paris)       Date:  1973-01       Impact factor: 2.607

4.  Evaluation of antithymocyte globulin in acute relapses of multiple sclerosis.

Authors:  T P Seland; T A Mc Pherson; M Grace; G Lamoureux; J G Blain
Journal:  Neurology       Date:  1974-01       Impact factor: 9.910

5.  Multiple sclerosis unaffected by azathioprine in pilot study.

Authors:  D Silberberg; R Lisak; B Zweiman
Journal:  Arch Neurol       Date:  1973-03

6.  Effect of 'maximum immune suppression' with thoracic duct drainage, ALG, azathioprine and cortisone in some neurological disorders.

Authors:  W Brendel; J Seifert; G Lob
Journal:  Proc R Soc Med       Date:  1972-06

7.  [Immunosuppressive agents in multiple sclerosis. Preliminary trials with Proresid].

Authors:  W Danielczyk
Journal:  Wien Med Wochenschr       Date:  1968-11-02

8.  Failure of basic protein therapy for multiple sclerosis.

Authors:  R E Gonsette; P Delmotte; L Demonty
Journal:  J Neurol       Date:  1977-08-18       Impact factor: 4.849

9.  [Immunodepressive therapy in neurology].

Authors:  P F Girard; G Aimard; H Pellet
Journal:  Presse Med       Date:  1967-04-22       Impact factor: 1.228

10.  A preliminary evaluation of azathioprine (Imuran) in the treatment of multiple sclerosis.

Authors:  W G Tucker; K H Kapphahn
Journal:  Henry Ford Hosp Med J       Date:  1969
View more
  24 in total

1.  Randomised double blind controlled trial of cyclosporin in multiple sclerosis.

Authors:  P Rudge; J C Koetsier; J Mertin; J O Mispelblom Beyer; H K Van Walbeek; R Clifford Jones; J Harrison; K Robinson; B Mellein; T Poole
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-05       Impact factor: 10.154

Review 2.  Cyclophosphamide for multiple sclerosis.

Authors:  L La Mantia; C Milanese; N Mascoli; R D'Amico; B Weinstock-Guttman
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

3.  The need for a new strategy for the treatment of multiple sclerosis.

Authors:  A N Davison
Journal:  J Neurol       Date:  1988-07       Impact factor: 4.849

4.  Short-term intensive cyclophosphamide treatment in progressive multiple sclerosis.

Authors:  G F Siracusa; M P Amato; L Fratiglioni; D Sità; L Amaducci
Journal:  Ital J Neurol Sci       Date:  1987-12

5.  Short-term intensive cyclophosphamide treatment in multiple sclerosis. A retrospective controlled study.

Authors:  P Theys; F Gosseye-Lissoir; P Ketelaer; H Carton
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

6.  Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.

Authors:  Daniel M Harrison; Douglas E Gladstone; Edward Hammond; Jeffrey Cheng; Richard J Jones; Robert A Brodsky; Douglas Kerr; Justin C McArthur; Adam Kaplin
Journal:  Mult Scler       Date:  2011-08-24       Impact factor: 6.312

7.  Intrathecal methylprednisolone acetate in multiple sclerosis treatment: effect on the blood-CSF barrier and on the intrathecal IgG production.

Authors:  B Rocchelli; M Poloni; P Mazzarello; G Piccolo; M Delodovici; P Pinelli
Journal:  Ital J Neurol Sci       Date:  1982-07

Review 8.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

9.  Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.

Authors:  W H Likosky; B Fireman; R Elmore; G Eno; K Gale; G B Goode; K Ikeda; J Laster; C Mosher; J Rozance
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-12       Impact factor: 10.154

10.  Effective treatment of chronically progressive multiple sclerosis with low-dose cyclophosphamide with minor side-effects.

Authors:  E Mauch; H H Kornhuber; U Pfrommer; A Hähnel; H Laufen; H Krapf
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.